Vertex Pharmaceuticals Inc
Close on Nov 2, 2026Market cap $140.20BP/E 32.2Yield –
Vertex Pharmaceuticals CRISPR Therapeutics Collaboration by Quarter
CRISPR Therapeutics Collaboration (CASGEVY JDCA, 60% VRTX / 40% CRISPR) — Net R&D expense ($M) ($M)
Vertex Pharmaceuticals CRISPR Therapeutics Collaboration: $14.4M in Q2 2026, down 4.6% from a year earlier.
Where the Q2 2026 figure comes from
Source: Form 10-Q (filed 2026-08-04) ↗
Reported in Form 10-Q / 10-K Note (Collaborative Arrangements — CRISPR Therapeutics).
Quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | CRISPR Therapeutics Collaboration (CASGEVY JDCA, 60% VRTX / 40% CRISPR) — Net R&D expense ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| Q2 2026 | Jun 30, 2026 | 14.4 | -4.6% | Form 10-Q (filed 2026-08-04) ↗ |
| Q1 2026 | Mar 31, 2026 | 16.1 | +0.6% | Form 10-Q (filed 2026-05-05) ↗ |
| Q4 2025 | Dec 31, 2025 | 16.8 | -594.1% | Form 10-K (filed 2026-02-13) ↗ |
| Q3 2025 | Sep 30, 2025 | 14.3 | +22.2% | Form 10-Q (filed 2025-11-04) ↗ |
| Q2 2025 | Jun 30, 2025 | 15.1 | +30.2% | Form 10-Q (filed 2026-08-04) ↗ |
| Q1 2025 | Mar 31, 2025 | 16 | +36.8% | Form 10-Q (filed 2026-05-05) ↗ |
| Q4 2024 | Dec 31, 2024 | -3.40 | -125.0% | Form 10-K (filed 2026-02-13) ↗ |
| Q3 2024 | Sep 30, 2024 | 11.7 | -6.4% | Form 10-Q (filed 2025-11-04) ↗ |
| Q2 2024 | Jun 30, 2024 | 11.6 | -35.2% | Form 10-Q (filed 2025-08-05) ↗ |
| Q1 2024 | Mar 31, 2024 | 11.7 | -34.6% | Form 10-Q (filed 2025-05-06) ↗ |
| Q4 2023 | Dec 31, 2023 | 13.6 | -115.1% | Form 10-K (filed 2026-02-13) ↗ |
| Q3 2023 | Sep 30, 2023 | 12.5 | -72.5% | Form 10-Q (filed 2024-11-05) ↗ |
| Q2 2023 | Jun 30, 2023 | 17.9 | -54.0% | Form 10-Q (filed 2024-08-02) ↗ |
| Q1 2023 | Mar 31, 2023 | 17.9 | -50.6% | Form 10-Q (filed 2024-05-07) ↗ |
| Q4 2022 | Dec 31, 2022 | -90.1 | +129.8% | Form 10-K (filed 2025-02-13) ↗ |
| Q3 2022 | Sep 30, 2022 | 45.5 | -22.5% | Form 10-Q (filed 2023-11-07) ↗ |
| Q2 2022 | Jun 30, 2022 | 38.9 | -29.3% | Form 10-Q (filed 2023-08-02) ↗ |
| Q1 2022 | Mar 31, 2022 | 36.2 | -9.5% | Form 10-Q (filed 2023-05-02) ↗ |
| Q4 2021 | Dec 31, 2021 | -39.2 | -157.8% | Form 10-K (filed 2024-02-15) ↗ |
| Q3 2021 | Sep 30, 2021 | 58.7 | +310.5% | Form 10-Q (filed 2022-10-28) ↗ |
| Q2 2021 | Jun 30, 2021 | 55 | – | Form 10-Q (filed 2022-08-05) ↗ |
| Q1 2021 | Mar 31, 2021 | 40 | – | Form 10-Q (filed 2022-05-06) ↗ |
| Q4 2020 | Dec 31, 2020 | 67.8 | – | Form 10-K (filed 2023-02-10) ↗ |
| Q3 2020 | Sep 30, 2020 | 14.3 | – | Form 10-Q (filed 2021-11-03) ↗ |
Breakdown
What makes up CRISPR Therapeutics Collaboration
- CRISPR Collaboration — Cost of sales / collaboration profit-sharing ($M)21.8 · Q2 2026
- CRISPR Collaboration — Pre-commercialization SG&A expense (historical, $M)10.9 · Q4 2023
- CRISPR Collaboration — Total collaboration expenses recognized (historical, $M)95.2 · Q4 2022
- CRISPR Collaboration — Vertex share of CASGEVY net profits / losses (%)4,000.0% · Q2 2026
- CRISPR Collaboration — Vertex share of program development costs (%)4,000.0% · Q2 2026
Cite this data
StockData. (2026). Vertex Pharmaceuticals CRISPR Therapeutics Collaboration ($M), quarterly Q3 2020–Q2 2026 [Data set]. Compiled from Vertex Pharmaceuticals SEC filings and investor materials. https://stockdatahq.com/stocks/vrtx/kpis/crispr-rd
See every metric in the Vertex Pharmaceuticals KPI table. Data updated Nov 2, 2026.